Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Epsilogen, a UK-based spinout of King’s College London working on cancer treatments that exploit immunoglobulin E antibodies, pocketed £30.75m ($41.2m) in a series B round backed by commercialisation firm Epidarex Capital yesterday. The round was led by Novartis Venture Fund on behalf of pharmaceutical firm Novartis, and also included Alsa Ventures, 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property. Epsilogen, then known as Item Therapeutics, previously closed a $6.4m series A round in 2018 backed by UCL Technology Fund, the venture fund of University College London, Epidarex, Alsa Ventures.

Alimetry, a New Zealand-based medical devices developer spun out of University of Auckland and focused on gastrointestinal diseases, completed a NZ$16.3m ($10.9m) round yesterday backed by tech transfer office Auckland UniServices and commercialisation firm IP Group. The round was led by Movac and also attracted Matū Karihi and K1W1. Alimetry emerged from stealth…

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).